BetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0888 USD | -1.83% | +1.49% | +85.00% |
Jun. 14 | BetterLife Pharma Raises $530,000 in Private Placement | MT |
May. 29 | BetterLife Pharma Inc. Reports Earnings Results for the Full Year Ended January 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+85.00% | 10.4M | |
+16.55% | 124B | |
+16.91% | 112B | |
+3.87% | 22.94B | |
-10.90% | 17.02B | |
-16.71% | 16.88B | |
-39.94% | 16.87B | |
+2.17% | 13.63B | |
+26.39% | 11.61B | |
+103.16% | 10.31B |
- Stock Market
- Equities
- BETRF Stock
- News BetterLife Pharma Inc.
- BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies